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Abstract: Colorectal cancer is an increasingly significant cause of mortality whose risk is linked to
diet and inversely correlated with cruciferous vegetable consumption. This is likely to be partly
attributable to the isothiocyanates derived from eating these vegetables, such as sulforaphane,
which is extensively characterised for cytoprotective and tumour-suppressing activities. However,
its bioactivities are likely to extend in complexity beyond those currently known; further insight
into these bioactivities could aid the development of sulforaphane-based chemopreventive or
chemotherapeutic strategies. Evidence suggests that sulforaphane modulates the expression of
microRNAs, many of which are known to regulate genes involved at various stages of colorectal
carcinogenesis. Based upon existing knowledge, there exist many plausible mechanisms by which
sulforaphane may regulate microRNAs. Thus, there is a strong case for the further investigation
of the roles of microRNAs in the anti-cancer effects of sulforaphane. There are several different
types of approach to the wide-scale profiling of microRNA differential expression. Array-based
methods may involve the use of RT-qPCR or complementary hybridisation probe chips, and tend to
be relatively fast and economical. Cloning and deep sequencing approaches are more expensive and
labour-intensive, but are worth considering where viable, for their greater sensitivity and ability to
detect novel microRNAs.
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1. Colorectal Cancer
Colorectal cancer is a major and increasingly common cause of morbidity and premature death.
Its global incidence was 1.4 million in 2012, according to the World Health Organization, and is rising,
making it the third most commonly diagnosed cancer [1]. In 2015, 774,000 mortalities were directly
attributable to colorectal cancer—a figure 58% higher than in 1990 [2]. It is rare for tangible symptoms
of colorectal cancer to present until it has already progressed to an advanced (usually terminal)
stage, at which currently available treatments are unable to provide a cure [3]. Therefore, strategies
for limiting the disease burden from colorectal cancers must include improvements to early-stage
diagnosis in asymptomatic individuals, as well as new preventive initiatives.
Reported incidence correlates positively with economic development and/or the adoption of
“Western” dietary patterns [4]. Increasing rates of chronic diseases such as cancers are inevitable
in countries experiencing rising living standards, partly due to reduced rates of premature death
from communicable diseases. Economic development also tends to facilitate improvements to public
and/or affordable private healthcare, leading to improved diagnosis. Nevertheless, there is compelling
evidence to suggest that commonly associated dietary and lifestyle changes have a significant impact
upon the development of colorectal cancer [5]. Particularly, one’s risk of developing colorectal cancer
is believed to be increased by obesity and a high intake of red meat and/or alcohol and reduced
by a fibre-rich diet abundant in fruits and vegetables and a physically active lifestyle, according to
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guidelines published by Bowel Cancer UK [6]. The apparently strong connections between diet
and colorectal cancer risk are unsurprising, given the inevitable exposure of the colorectal tissues to
ingested compounds and products of the gut microbiota. The apparently protective effects of diets
rich in plant-based foods are believed to be largely attributable to the phytochemicals found in them,
many families of which have been studied regarding their direct biological (often cytoprotective)
activity—both in vitro and in vivo—since the middle of the twentieth century.
2. Cruciferous Vegetables
Epidemiological studies have revealed a particular inverse correlation between the intake of
cruciferous vegetables and colorectal cancer risk; one stronger than that between the latter and the
intake of other vegetables [7,8]. Cruciferous vegetables refer to those of the Brassicaceae family and
include broccoli, cabbage, and Brussel sprouts. Particular to this plant family are glucosinolates—a
group of compounds endogenously synthesised and derived from glucose and amino acid residues.
Upon the rupture of plant cells—such as occurs from the consumption of the vegetables or from
parasitic attack—the glucosinolates are able to be hydrolysed by endogenous myrosinase enzymes.
Intact plant tissue separates glucosinolates from myrosinase enzymes by compartmentalising the
former in S-cells [9] and the latter in myrosin cells [10]. Only upon cell rupture are the myrosinase
enzymes able to hydrolyse the glucosinolates. Several types of compound are potentially formed,
including isothiocyanates, thiocyanates, and nitriles [11].
3. Sulforaphane
Isothiocyanates are to date the most-studied and best-characterised of known glucosinolate-
hydrolysis-derived products in terms of their bioactivity. They are believed to play a defensive
role in the plants via their cytotoxic effects on microorganisms and small parasitic animals,
but to be directly beneficial to human health via broad anti-inflammatory and antioxidant
effects, and thus are able to help inhibit the development of cancers [12], cardiovascular
diseases [13], and osteoarthritis [14,15]. Broccoli is particularly high in a particular glucosinolate
called glucoraphanin, whose myrosinase-mediated hydrolysis generates an isothiocyanate called
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where  it  transcriptionally activates various genes,  including  those coding  for antioxidant proteins 
such as thioredoxin reductase 1 [22] and uridine diphosphate (UDP)‐glucuronosyltransferases [23]. 
These antioxidant proteins act to reduce reactive oxygen species (ROS) levels. ROS can react non‐
specifically with and  thereby damage macromolecules  such as  lipids, proteins, nucleic acids and 
carbohydrates, promoting DNA damage–associated mutation and inflammatory signaling linked to 
age‐related decline of function and the pathogeneses of chronic conditions such as atherosclerosis, 
Figure 1. The molecular struct re of -isothiocyanato-4-(methylsulfiny )butane), also known
as sulforaphane.
A multitude of experiments in vitro and in vivo reportedly demonstrate the ability of SFN to both
defend healthy cells against chemical and/or radiation-induced carcinogenesis [16–18] and to inhibit
the proliferation, migration, invasive potential and urvival of tumour cells [19–21]. It is likely that
the former, cytoprotective function of SFN is largely attributable to the induction of nuclear factor
(erythroid-derived 2)-like 2 (Nrf2), resulting from the separation of cytoplasmic Nrf2 from Kelch-like
ECH-associated protein 1 (Keap1), as ill st ated in Figur 2. This allows Nrf2 to enter the nucleus,
where it transcriptionally activates various genes, including those coding for antioxidant proteins such
as thioredoxin reductase 1 [22] and uridine diphosphate (UDP)-glucuronosyltransferases [23]. These
antioxidant proteins act to reduce reactive oxygen species (ROS) levels. ROS can react non-specifically
with and thereby damage macromolecules such as lipids, proteins, nucleic acids and carbohydrates,
promoting DNA damage–associated mutation and inflammatory signaling linked to age-related decline
of function and the pathogeneses of chronic conditions such as atherosclerosis, neurodegenerative
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diseases and cancers. Therefore, a hypothesis popular in the middle of the twentieth century demonised
ROS as toxic metabolic by-products, whose elimination could even halt the “ageing process” [24].
However, it has since been proven that ROS are vital for life and health, as essential components of
cell-signaling pathways. For example, the glucose-induced secretion of insulin by β-pancreatic cells
is dependent upon glucose-induced ROS generation [25]. Additionally, hydrogen peroxide binds to
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Figure  2. An  illustration of  the mechanisms by which  sulforaphane  (SFN)  can  induce Nrf2.  SFN 













dissociation  [30]. At  low‐to‐moderate doses,  the  ensuing antioxidant  response  tends  to outweigh 
those of the initial oxidative stress in redox terms, leading to a net protection against oxidative stress 
[31]. This  is believed  to be  largely  responsible  for SFN’s cytoprotective potential  in healthy cells. 
However,  very  high  doses  of  SFN  can  be  cytotoxic  if  the  pro‐oxidant  effects  induce  significant 
macromolecular damage and/or ROS‐mediated apoptosis before  the mounting and execution of a 
sufficient antioxidant response, as illustrated by the sketch in Figure 3. This probably underlies the 
toxicity of SFN  towards microorganisms and parasitic  insects, as well as  its observed abilities  to 
inhibit tumour cell survival and metastasis [32]. The redox‐modulating effects of SFN can thus be 
described as an example of hormesis. Hormesis is an ancient concept long characterised in various 
literature  for  medicinal  and/or  poisonous  herbs—and  more  recently  in  scientific  literature  for 
nutrients, phytochemicals, and pharmaceutical drugs. In hormesis, low dose‐exposure to a particular 
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Figure 2. An illustration of the mechanis s by which sulforaphane (SFN) can induce Nrf2. SFN
d pletes intracellular GSH by forming c es with it, and also inh bits complex III of the
mitochondrial respiratory chain, thus incre si OS levels. This acute increase in ROS causes Nrf2
to dissociate from Keap1, thereby enabling it to enter the nucleus where it transcriptionally activates
antioxidant genes via ARE binding.
SFN is commonly referred to as an “antioxidant” based on its widely demonstrated ability to help
protect cells against oxidative stress at low-to-moderate doses [27]. However, SFN actually has an
acute pro-oxidant effect in cells, largely by depleting intracellular glutathione due to the formation
and export of SFN-glutathione complexes [28]. SFN can also increase mitochondrial ROS generation
by inhibiting complex III of the mitochondrial respiratory chain, which causes the accumulation
of ubisemiquionine, from which molecular oxygen receives electrons, resulting in the formation of
superoxide and hydrogen peroxid [29]. SFN-induced acute oxida ive tress is widely believed to be
a significant driver of SFN-mediated Nrf2 induction, in addition to the SFN-mediate inhibition of
p38 mitogen-activated protein kinase (MAPK), whose phosphorylation of Nrf2 inhibits Nrf2-Keap1
dissociation [30]. At low-to-moderate doses, the ensuing antioxidant response tends to outweigh those
of the initial oxidative stress in redox terms, leading to a net protection against oxidative stress [31].
This is believed to be largely responsible for SFN’s cytoprotective potential in healthy cells. However,
very high doses of SFN can be cytotoxic if the pro-oxidant effects induce significant macromolecular
damage and/or ROS-mediated apoptosis before the mounting and execution of a sufficient antioxidant
respons , as illustrated by the sketch in Figure 3. This probably underlies the toxicity of SFN towards
microorganisms and par sitic insects, as well as its observed abilities to inhibit t mour cell survival and
metastasis [32]. The redox-modulating effects of SFN can thus be described as an example of hormesis.
Hormesis is an ancient concept long characterised in various literature for medicinal and/or poisonous
herbs—and more recently in scientific literature for nutrients, phytochemicals, and pharmaceutical
drugs. In hormesis, low dose-exposure to a particular substance or stimulus has a net beneficial impact
(in the case of sulforaphane, oxidative stress-inhibiting) upon the host that are consequential to the
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protective response it initiates. On the other hand, the net effects of higher dose-exposure are opposite
and adverse (in the case of sulforaphane, oxidative stress-inducing) [33]. Doses obtainable from the
consumption of cruciferous vegetables by humans are far below the cytotoxic threshold, thus tend to
confer either neutral or cytoprotective effects. For example, one study has demonstrated plasma SFN
concentrations to reach 10µM following the consumption of broccoli sprouts by study participants [34],
which is a concentration demonstrated as non-cytotoxic, Nrf2-inducing and cytoprotective in various
cell lines and systems.
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ROS  are  not  the  only potential means  by which  high‐dose  SFN  could  repress  the  survival, 
proliferation, and metastatic  characteristics of  tumour  cells. SFN  can  induce  tumour‐suppressing 
epigenetic changes by directly inhibiting histone deacetylases [40], some of which have a tendency to 
be aberrantly upregulated in colorectal cancer, thereby repressing various tumour suppressor genes 
at  the  transcriptional  level via chromatin deacetylation  [41]. However, another potential and  less 
comprehensively  studied means  by which  SFN may  interact with  cancers  is  the modulation  of 
microRNA (miRNA) expression. 
MiRNAs are  small non‐coding RNAs  that are  typically 18‐25 nucleotides  in  length and  that 
originate from various genetic loci such as the exons or introns of protein‐coding genes and long non‐
coding exonic clusters (arrays). They post‐transcriptionally regulate the expression of at least 30% of 
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playing major roles in human development and health. Unsurprisingly, major roles for miRNAs in 
carcinogenesis are frequently reported [43], which is interesting in light of the apparent potential for 
SFN  to modulate miRNA expression  in  several colorectal cell  lines  [44]. This  leads  to  reasonable 
assumption that miRNA modulation has a role to play in SFN’s complex interactions with colorectal 
cancer. 
Figure 3. A sketch illustrating the hormetic effects of sulforaphane on cells with regards to oxidative
stress, in that net reduction of oxidative stress is observed upon exposure to moderate doses, whereas
increased oxidative stress and/or cytotoxicity occurs from high exposure.
Clearly, the induction of Nrf2 in healthy cells tends to be desirable from an anti-cancer perspective
due to the inhibition of potentially carcinogenic ROS-induced mutation. In tumour cells, however,
it can enhance their survival and proliferation, and make them more resistant to cytotoxicity-dependent
anti-cancer therapies [35]. Nrf2 hyperactivation is in fact a marked feature of some cancers and a
significant contributor to their aggressiveness. Thus, it has even been speculated that cytoprotective
doses of SFN might be detrimental to patients undergoing treatment for advanced cancers, due to
the induction of Nrf2 in tumour cells [36]. However, it is important to note that Nrf2 induction does
not necessarily boost cell proliferation—particularly in early-stage tumour cells—and has in fact been
reported to repress the proliferation of lung-cancer cells by inducing the breakdown of polyamines [37],
whilst even t be respons ble f r the anti-prolif ve effects of allicin in HCT-116 cells [38]. N f2 can
also upregulate the surface expression of IL-17D, which in a systemic context coul facilitate natural
killer cell-mediated cell death in tumours [39]. Therefore, it is apparent that the interactions between
SFN and redox status, and between redox status and carcinogenesis, are complicated.
4. MicroRNAs
ROS are not the only potential means by which high-dose SFN could repress the survival,
proliferation, and metastatic characteristics of tumour cells. SFN can induce tumour-suppressing
epigenetic changes by directly inhibiting histone deacetylases [40], some of which have a tendency
to be aberrantly upregulated in colorectal cancer, thereby repressing various tumour suppressor
genes at the transcriptional level via chromatin deacetylation [41]. However, another potential and
less comprehensively studied means by which SFN may interact with cancers is the modulation of
microRNA (miRNA) expression.
MiRNAs are small non-coding RNAs that are typically 18-25 nucleotides in length and that
originate from various genetic loci such as the exons or introns of protein-coding genes and long
non-coding exonic clusters (arrays). They post-transcriptionally regulate the expression of at least
30% of protein-co ng genes in humans [42] by modulating messenger RNA (mRNA) translation,
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thus playing major roles in human development and health. Unsurprisingly, major roles for
miRNAs in carcinogenesis are frequently reported [43], which is interesting in light of the apparent
potential for SFN to modulate miRNA expression in several colorectal cell lines [44]. This leads to
reasonable assumption that miRNA modulation has a role to play in SFN’s complex interactions with
colorectal cancer.
4.1. Biogenesis
The canonical pathway of miRNA biogenesis begins with the RNA polymerase II-mediated
transcription of a long 5′-capped and 3′-polyadenylated transcript (the pri-miRNA), which is
subsequently cleaved by DiGeorge Syndrome Critical Region 8 (DGCR8) to form products with
distinctive hairpin-loop structures and 3′ 2-nucleotide overhangs (the pre-miRNAs) (Figure 4).
The overhangs are recognised by exportin 5, which subsequently exports the pre-miRNAs to the
cytoplasm where the same overhangs are recognised by Dicer [45]. A pre-miRNA may alternatively be
formed by the conversion—by the lariat debranching enzyme (Ldbr)—of an intronic tract released
upon the maturation of a protein-coding mRNA [46]. Dicer cleaves pre-miRNAs in their loop
regions to generate linear duplexes, which are then unwound, and one strand from each of which
remains Dicer-bound, then together with Dicer and Argonaute (AGO) proteins becomes part of an
RNA-induced silencing complex (RISC) [45]. These single-stranded Dicer-bound RNAs are the mature
miRNAs. Mature miRNAs can alternatively be generated non-canonically via the direct processing of
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their 3’ ends.  (3) The 3’ 2‐nucleotide overhangs are  recognised by Exportin 5, which uses GTP  to 
transport  them  from  the nucleus  to  the cytoplasm.  (4) Dicer recognises  the same 3’ overhang and 
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as  evidence  against  this phenomenon  being  true  in  the majority  of  cases  accumulated, miRBase 
nomenclature  was  changed  such  that  the  “*”  suffix  was  dropped,  and  mature  miRNAs  were 
appended with “‐5p” or “‐3p” suffixes to denote  the pre‐miRNA arm of origin. According  to  this 
nomenclature, any mature miRNA names lacking a suffix are assumed to denote the only pre‐miRNA 
Figure 4. A diagram illustrating the canonical pathway of miRNA expression in animal cells. (1) A
genetic locus is transcribed by RNA polymerase II, producing a pri-miRNA, which is several hundred
n cleotides long. (2) The pri-miRNA is bound by DGCR8, which recruits Drosha, which cleaves the
pri-miRNA into pre-miRNAs that are about 70 nucleotides long and have 2-nucleotide overhangs
at their 3′ ends. (3) The 3′ 2-nucleotide overhangs are recognised by Exportin 5, which uses GTP to
transport them from the nucleus to the cytoplasm. (4) Dicer recognises the same 3′ overhang and makes
a nick in the loop region of the pre-miRNA, generating an imperfectly paired linear RNA duplex, each
strand of which b ars a 3′ 2-nucleotide overhang. (5) The linear RNA duplex is unwound; one strand
remains associated with Dicer as the mature miRNA, and becomes part of a RISC upon association
with AGOs.
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4.2. Notes on Nomenclature
From each pre-miRNA, two mature miRNAs may be formed; one from each arm of the
hairpin-loop motif. It was once assumed that only one of these tended to be functional (typically that
with lower stability at the 5′ end), and that that from the other arm was degraded. Therefore—of
the two mature miRNAs potentially formed from the processing of pre-miR-29b—the “dominant”
product would have been called “miR-29b” whilst the other would have been termed “miR-29b*”.
However, as evidence against this phenomenon being true in the majority of cases accumulated,
miRBase nomenclature was changed such that the “*” suffix was dropped, and mature miRNAs were
appended with “-5p” or “-3p” suffixes to denote the pre-miRNA arm of origin. According to this
nomenclature, any mature miRNA names lacking a suffix are assumed to denote the only pre-miRNA
processing product thus far identified. This updated miRBase nomenclature is used throughout
this review.
4.3. Activities
The canonical mechanism of miRNA-mediated repression begins with the interaction of a
6–8 nucleotide seed region at the 5′ end of the miRNA with a locus or loci in the 3′-untranslated
region (3′-UTR) of the mRNA, with which it is at least partially complementary in sequence. The RISC
represses the translation of and/or degrades the bound mRNA, although the triggering of degradation
is believed to be relatively rare in mammals, and to require perfect complementarity between the
miRNA seed region and mRNA 3′-UTR [48]. AGO2 is the only AGO in mammals thus far shown to
possess endonuclease activity [49]. Since only partial complementarity is required for translational
repression, any given miRNA has the potential to target many different mRNA transcripts, whilst any
given mRNA is potentially targeted by a multitude of miRNAs.
Although typically characterised as translational repressors, there are contexts in which an
miRNA may conversely upregulate the translation of its target. For example, miR-369-3p promotes
the translation of its target—tumour necrosis factor-α (TNF-α)—under serum-starved conditions,
but represses it under normal conditions [50] as illustrated in Figure 5. This is facilitated by the
association of the miRNA with AGO2 specifically, which itself is facilitated by the association of fragile
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an AU‐rich  element  toward  the  3’  end, which  is  required  for  its miRNA‐mediated  translational 
upregulation  [50].  MiR‐10a‐5p  was  demonstrated  to  bind  immediately  downstream  of  5’‐
oligopyrimidine motifs  present  in  the  5’‐UTRs  of  ribosomal  protein mRNAs,  and  consequently 
upregulate their translation under amino acid starvation, in E14 ES mouse embryonic stem cells [51]. 
It has been proposed  that miRNAs have a  tendency  to  repress  the  translation of  their  targets  in 
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typically  represses  the  transcription  of  a  tumour‐suppressing  myeloid  differentiation  factor, 
CCAAT/enhancer‐binding protein α—in chronic myeloid  leukaemia  [53]. MiR‐328‐3p  thereby de‐
represses  this  tumour suppressor gene, and  is demonstrably under‐expressed  in chronic myeloid 
leukaemia [54]. 
Figure 5. A diagram illustrating the ability of miR-369-3p to upregulate its target TNF-α under
starvation, but to conversely repress it under normal conditions.
Hypothetically, serum-starvation could impact the solubility and/or localisation of AGO2-FXR1
complexes in a manner that promotes their association with miR-369-3p. The TNF-α transcript
has an AU-rich element toward the 3′ end, which is required for its miRNA-mediated
translational upregulation [50]. MiR-10a-5p was demonstrated to bind immediately downstream
of 5′-oligopyrimidine motifs present in the 5′-UTRs of ribosomal protein mRNAs, and consequently
upregulate their translation er amino acid starvation, in E14 ES ouse embryonic stem
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cells [51]. It has been proposed that miRNAs have a tendency to repress the translation of
their targets in dividing cells, but conversely promote such in quiescent cells [52]. The apparent
dependence of miRNA-mediated effects on nutritional status could be important when considering
the roles of miRNAs at different stages of carcinogenesis, and in the context of certain therapies.
Some miRNAs have been demonstrated to have RISC-independent effects, such as acting as decoys
for RNA-binding proteins. For example, miR-328-3p acts as a decoy for the hnRNP E2 RNA-binding
protein—which typically represses the transcription of a tumour-suppressing myeloid differentiation
factor, CCAAT/enhancer-binding protein α—in chronic myeloid leukaemia [53]. MiR-328-3p thereby
de-represses this tumour suppressor gene, and is demonstrably under-expressed in chronic myeloid
leukaemia [54].
4.4. IsomiRs
Both at the cleavage of pri-miRNAs to form pre-miRNAs, and of the latter to form mature miRNAs,
the Drosha and Dicer enzymes do not necessarily cleave at a precise locus, but have the potential
to “slip” by several nucleotides in either direction [55]. Therefore, the mature miRNA sequences
catalogued in miRBase do not necessarily represent specific RNAs of fixed sequence, but rather
consensus sequences of distributions of isoforms that vary from the consensus in the form of having
additional or missing nucleotides at either end. Such variant isoforms are called isomiRs. Perhaps
the isomiR phenomenon evolved in cases where several isomiRs of a given miRNA all target a given
mRNA in a desirable fashion, but affect different undesirable “off-target” mRNAs—i.e., the presence
of multiple isomiRs could provide a mechanism for intensifying the desirable regulation of a specific
mRNA target, whilst diffusing undesirable side-effects on other mRNAs [56].
5. Linking Sulforaphane, MicroRNAs, and Colorectal Cancer
A Google Scholar search was performed on 17th February 2017, using the following
search string: intitle:microrna|mirna|micrornas|mirnas|”mir-“intitle:colorectal|colon|rectal|bowel
intitle:cancer|tumour|tumor|cancers|tumours|tumors|carcinogenesis|tumorigenesis. This revealed
existing reports of 144 miRNAs with apparent functions in colorectal cancer—of these, 85 were
apparently tumour suppressive, 45 oncogenic, and 14 ambiguous in that reports of both oncogenic
and tumour-suppressive function were found. Some examples of each are listed in Table 1, along with
reported target genes.
Table 1. Listed examples of reportedly tumour suppressive, oncogenic and ambiguous miRNAs and
their reported target genes.







miR-143-5p DNMT3A [61]; ERK5 [62]
miR-195-5p BCL2 [63]
miR-200a-3p CTNNB1 [64]








miR-135b-5p TGFβR2, DAPK1, APC [72]
miR-9-5p Ambiguous CDH [73]; TM4SF1 [74]
miR-21-5p Pdcd4 [75]; CDC25A [76]; TGFβR2 [77]
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The apparent involvement of many miRNAs in colorectal cancer is unsurprising, given the
major roles of miRNAs in human health and development. There is also existing evidence to suggest
that miRNA expression can be modulated in non-cancerous colonic cell lines by SFN. For example,
Slaby et al. reported that SFN appeared to upregulate miR-9-3p, miR-23b-3p, miR-27b-5p, miR-27b-3p,
miR-30a-3p, miR-135b-3p, miR-145-5p, miR-146a-5p, miR-342-3p, miR-486-5p, miR-505-3p, miR-629-5p,
and miR-758-3p, but to downregulate miR-106a-3p, miR-155-5p, and miR-633-3p [44]. Two cell
lines—normal derived colon mucosa 460 (NCM460) and normal derived colon mucosa 356
(NCM356)—were used, and TaqMan Low Density qPCR Arrays were used to profile the differential
expression of 754 human miRNAs following 48 h SFN treatment [44]. This is a convincing indicator
that SFN is able to modulate miRNA expression in colorectal cells, although it is important to note
that the miRNAs reported as differentially expressed were not confirmed as so by additional assays.
Also, only non-cancerous cell lines and a single time point post-treatment were studied, whereas
the effects in cancerous colonic cells might differ substantially from those in their non-cancerous
counterparts, and certain miRNAs may be transiently modulated at earlier time points in response to
SFN treatment.
Therefore, further experiments to profile the modulation of miRNA expression at different time
points, and in a cancerous colorectal cell line, could add significantly to the findings of Slaby et al.
as illustrated in Figure 6. It would also be prudent to further examine miRNAs that are reportedly
differentially expressed according to the wide-scale profiling process, using single-target assays,
in order to rule out the possibility of them being artefacts of the former. Encouragingly, a human study
reportedly showed that the consumption of 160g broccoli/day by participants was able to alter blood
miRNA expression profiles, thus indicating that systemic regulation of miRNA expression in vivo is
possible by doses of SFN obtainable from typical consumption of broccoli, although it cannot be ruled
out that the observed modulations were mediated by components of broccoli other than SFN, such as
fibre, and selenium and/or other micronutrients [78].
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Figure 6. A basic overview of the miRNA-profiling experiments carried out by Slaby et al. and
suggested further experiments. Slaby et al. treated non-cancerous colonic cell lines with sulforaphane,
then profiled differences in miRNA expression at 48 h. Possible further experiments involving colorectal
cancer cell lines and additional time points are illustrated and highlighted in yellow.
5.1. Mechanisms of Sulforaphane-M diated M dulation
The possible mechanisms by which SFN may modulate miRNA expression are wide-ranging and
could involve downstream effects of the SFN-mediated modulation of histone deacetylase (HDAC)
activity, redox status, inflammatory signalling, miRNA-processing protein expression, and induction
of Nrf2. For example, SFN is known to inhibit the activity of several HDACs [34] including HDAC3,
which itself transcriptionally repressed the pro-apoptotic miR-15a-5p/16-1-5p cluster in mantle
cell lymphoma cells [79]. SFN (15 µM) was also reported to directly inhibit HDAC3 activity in
colorectal cancer HCT-116 cells, thereby inhibiting their proliferation, whilst having no similar effect
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in non-cancerous colonic CCD-841 cells [41]. SFN is also known to affect redox status—via its
acute pro-oxidant and/or Nrf2-inducing effects—which can affect miRNA expression in various
ways. For example, oxidative stress has been reported to inhibit Dicer activity in JAR trophoblast
cells [80], to inhibit the Drosha partner protein DGCR8 [81], to activate Drosha via glycogen synthase
kinase 3β activation [81], to inhibit adenosine diphosphate (ADP)-ribosylation and thus activity
of AGO2 [82], and to induce ER stress such that induces an endoribonuclease (RNAse) called
inositol-required enzyme 1α that can degrade the pre-miRNAs typically giving rise to miR-17-5p,
miR-34a-5p, miR-96-5p and miR-125b-5p [81]. Interestingly, SFN-mediated Nrf2 induction may
have additional, redox-independent consequences, since the 5′ flanking regions of certain miRNA
genetic loci possess the antioxidant responsive element (ARE), as is found in the promoter regions
for antioxidant protein-coding genes [83]. Nrf2 was reported to transcriptionally downregulate
miR-29b-3p via ARE binding [83], but to upregulate the transcription of the mir-125b-1 and mir-29b-1
pre-miRNAs in acute myeloid leukaemia cells [84].
The anti-inflammatory effects of SFN are likely to also play a role in SFN-mediated miRNA
modulation; an inflammatory medium containing TNF, IL-6, IL-8, and IL-1β was reported to
upregulate miR-155-5p in several breast cancer cell lines, and miR-146a-5p in the HCT-15 and HCT-116
colorectal cancer cell lines [85]. Finally, proteins involved in miRNA biogenesis, including RNA
polymerase II, Dicer, Drosha, DGCR8, Exportin 5, Ldbr and AGOs, are all potentially susceptible
to SFN-mediated modulation. Further complicating the picture are considerations that HDAC
activity, redox status, inflammatory signalling, miRNA-processing protein expression and Nrf2 can
all cross-interact, as illustrated in Figure 7. For example, ROS can inhibit HDACs and activate
histone acetyltransferases [86], whilst reciprocally, the ROS-generating DUOX nicotinamide adenine
dinucleotide phosphate (NADPH) oxidases tend to be hypermethylated in lung cancer cell lines [87].
Inflammatory processes tend to reduce extracellular pH [88], which can promote H3 and H4
deacetylation [89]. Conversely, the HDAC inhibitor ITF2357 was reported to inhibit inflammatory
cytokine expression in LPS-stimulated peripheral blood mononuclear cells [90].
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Figure 7. A diagram to illustrate the complexity of the network of cross-interactions between potential
mechanisms of SFN-mediated miRNA modulation.
5.2. Interaction of MicroRNAs with Pathogenesis
The potential for miRNAs to interact with colorectal cancer pathogenesis at different stages is vast.
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5.2.1. Interaction with Classic Vogelstein-Model Pathogenesis
According to the canonical Vogelstein model of colorectal cancer pathogenesis [91]—which is
summarised in Figure 8—tumorigenesis typically begins with a reduction in adenomatous polyposis
coli (APC) activity, resulting in increased β-catenin activity. β-catenin facilitates the formation
of an aberrant crypt focus (ACF) via the upregulation of cell proliferation and stem cell renewal.
There are two miRNAs commonly overexpressed in colorectal cancer specimens—miR-135a-5p and
miR-135b-3p—which are both able to repress the translation of the APC protein [92], whilst miR-17-5p
has been reported to also promote β-catenin activity [93]. Conversely, miR-320a has been shown to
repress β-catenin and thereby inhibit tumour growth [93]. The next stage of pathogenesis according
to the Vogelstein model is the upregulation of KRAS activity—believed to typically result from
hyperactivating KRAS mutations. This leads to further acceleration of cell proliferation and the
progression of the ACF to an early adenoma [91]. MiR-18a-5p, miR-18a-3p, miR-143-3p, and several
let-7 miRNAs have all been demonstrated to translationally repress KRAS [92,93]. The following
stage of pathogenesis according to the Vogelstein model is the loss of the apoptotic DCC gene and the
TGF-β-driven tumour suppressor genes SMAD2 and SMAD4, and subsequent progression from an
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catenin, which promotes cell proliferation and stem cell renewal. (2) Increased KRAS activity further 
promotes proliferation and  the  formation of an early adenoma.  (3) The  tumour  suppressor genes 
DCC, SMAD2, and SMAD4 are lost, resulting in progression to a late adenoma. (4) The loss of p53 
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Interestingly,  miR‐224‐5p  and  the  miR‐130a/301a/454‐3p  family  have  all  been  reported  to 




by  its ability to  induce the miR‐34a‐c  family,  including miR‐34a‐5p, which can repress the HDAC 
sirtuin  1  [92].  This miRNA  is  typically  induced  in  response  to DNA  damage  in  a  largely  p53‐
dependent  manner,  and—along  with  other  members  of  its  family—tends  to  be  deleted  or 
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Figure 8. An illustration of the classic Vogelstein model of colorectal carcinogenesis and the reported
potential interactions of miRNAs with each stage. (1) A reduction in APC activity derepresses β-catenin,
which promotes cell proliferation and stem cell renewal. (2) Increased KRAS activity further promotes
proliferation and the formation of an early adenoma. (3) The tumour suppressor genes DCC, SMAD2,
and SMAD4 are lost, resulting in progression to a late adenoma. (4) The loss of p53 facilitates the
eventua progression of the late adenoma to a malignant ca cer.
Nutrients 2017, 9, 902 11 of 19
Interestingly, miR-224-5p and the miR-130a/301a/454-3p family have all been reported to directly
repress SMAD4, whilst miR-106a-5p and miR-21-5p have been shown to repress the transforming
growth factor (TGF)-β receptor II [93]. The final stage of pathogenesis according to the Vogelstein
model, in which the tumour develops into a malignant cancer, is the loss of p53 activity—typically via
the mutational inactivation of TP53 [91]. Tumour suppression by p53 is partly mediated by its ability
to induce the miR-34a-c family, including miR-34a-5p, which can repress the HDAC sirtuin 1 [92].
This miRNA is typically induced in response to DNA damage in a largely p53-dependent manner,
and—along with other members of its family—tends to be deleted or hypermethylated in colorectal
cancer specimens [93].
5.2.2. Alternative Pathogenesis Model Interaction
As illustrated in Figure 9, there are many other miRNAs with the potential to interact with
colorectal carcinogenesis additional to those mentioned above. For example, miR-144-3p and miR-25-3p
are reported to repress the mTOR and SMAD7 oncogenes, respectively, the latter of which may inhibit
TGF-β’s tumour suppressive functions [93]. MiR-145-5p is able to inhibit growth factor-induced
proliferation by repressing the insulin-like growth factor-1 receptor and insulin receptor substrate,
whilst miR-126-3p can repress p85β—a promoter of the oncogenic phosphoinositide 3-kinase (PI3K)
signalling pathway [92]. MiR-21-5p can conversely upregulate this oncogenic pathway by repressing
phosphate and tensin homolog (PTEN), and miR-103-3p can repress the tumour suppressor gene
KLF4 [92]. MiR-26a-5p has been shown to be able to interact with cancer cell metabolism in the
form of promoting aerobic glycolysis (i.e., the Warburg effect) by repressing pyruvate dehydrogenase
protein X component, and thus the mitochondrial synthesis of acetyl-coenzyme A from pyruvate [94].
The Warburg effect can metabolically enhance the accumulation of intermediates that are involved in
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Figure 9. A diagram illustrating the interaction of miRNAs with genes and pathways regulating the
pathogenesis of colorectal cancer.
To summarise, there is much published evidence to suggest that miRNAs are involved in
the pathogenesis of colorectal cancer, and that SFN is likely to modulate miRNA expression in
the colorectum. Based upon existing knowledge regarding SFN’s bioactivity, there are many
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plausible mechanisms by which SFN might modulate miRNA expression. There are also many
reports of specific miRNAs regulating tumour suppressor genes and/or oncogenes known to be
involved in colorectal carcinogenesis. Together, these premises present a strong case for the further
investigation of SFN-mediated miRNA modulation in cancerous and/or non-cancerous cell lines,
and its possible implication for SFN’s potential to interact with colorectal cancers at different stages
and in various contexts.
6. MicroRNA Assay Methods
6.1. Array-Based Methods
There are several types of wide-scale miRNA expression profiling methods that are frequently
used, including the miRNA RT-qPCR array technique employed by Slaby et al. for which the TaqMan
Low Density Array kit and human Megaplex RT Primer Pool v3.0 were used [44]. Such methods run
hundreds of RT-qPCRs in parallel—each specific for a different miRNA—and by nature are relatively
fast and economical with regards to required RNA sample input and overall cost. An alternative
array-type approach involves the use of a miRNA array hybridisation chip—a medium coated with
probes of sequence antisense to those of known miRNAs, to which miRNAs in samples can be
hybridised, and which generate signals in response to the quantity of material bound to each specific
probe [96]. Similarly to the RT-qPCR array method, this also tends to be relatively fast and economical.
However, both of these approaches come with certain caveats. The range of detectable miRNAs is
limited to those known at the time of development of the particular assay kit(s) used, which is an issue
given that the database of known human miRNAs continues to grow; miRBase v.14 was released at the
beginning of 2010 and catalogued 894 human miRNAs, whilst by the release of miRBase v.20 in the
middle of 2013 there were 2555, and the current release, v.21, catalogues 2588 [97]. These approaches
also come with sensitivity limitations.
6.2. Cloning and Deep Sequencing
An approach different to those described above, and with a number of advantages, is to clone all of
the miRNAs present in a given sample into libraries, and then subject the libraries to deep sequencing,
the data from which are analysed to evaluate the differential expression of known miRNAs, as well as
to identify potentially novel miRNAs [98]. Data can be retained and later re-mapped to updated lists
of miRNAs from later releases of miRBase. The cloning-sequencing approach also tends to be more
sensitive in terms of profiling the differential expression of known miRNAs. The typical workflow for
such experiments tends to begin with the ligation of 5′- and 3′-adapter oligomers to all small RNAs
present in samples, followed by the reverse transcription of all adapter-ligated RNA to complementary
DNA (cDNA). The cDNA products are then amplified by PCR and then size-separated by PAGE,
in order to separate cloned miRNAs from clones of different types of small RNA [99]. Cloned miRNAs
are then subject to deep sequencing, and the data generated are normalised and analysed to identify
known human miRNAs that are differentially expressed between different conditions.
One challenge presented by this process is the inevitable sequence-dependence bias towards
certain miRNAs over others in the adapter-ligation step, which results in the “favoured” miRNAs
being more abundantly cloned and thus appearing more abundant upon analysis of deep sequencing
data [98]. Such ligation bias should not impact the apparent differential expression of any given
miRNA across different samples, given that a bias towards a specific miRNA would occur equally
across all samples if the same adapters are used. However, one issue of ligation bias is the potential
for certain miRNAs to go undetected, if strongly “disfavoured” by the ligation process. In order
to mitigate ligation bias, HD adapter pools were developed by the Dalmay laboratory by adding
to then-existing Illumina 5′- and 3′- adapters, four nucleotides at random, at the ligating ends [98].
This means that instead of single 5′- and 3′-adapters being used, pools consisting of 256 variants
each are generated—each of which have different miRNA ligation bias profiles. These adapter pools
Nutrients 2017, 9, 902 13 of 19
have been demonstrated to dramatically increase miRNA coverage and to enable the detection of
novel miRNAs [98]. A method of miRNA library construction using Dalmay HD adapters has been
published by Xu et al. [99].
The main disadvantages of miRNA cloning-sequencing methods vs. the previously discussed
array-based approaches are the greater cost and time involved, both for the construction and the
sequencing of the libraries. However—where viable with regards to time and economics—investment
in the cloning-sequencing approach could be worthwhile for the potential additional knowledge
regarding differential miRNA expression obtained. It is also conceivable that overall costs may
continue to decrease over time as a result of ongoing technological development, as per recently
observable trends [100].
6.3. Comparison of Approaches to MicroRNA Profiling
A brief comparison of the above-discussed types of approach to the wide-scale profiling of miRNA
expression is provided in Table 2.
Table 2. A brief comparison of array-based and library construction-sequencing-based approaches to
wide-scale miRNA expression profiling.
Type of Method Cost Relative Time Required MiRNA Detection
Array Medium Low Limited to miRNAs known at the time ofarray development.
Library-Sequencing High High
Can identify and assay novel miRNAs, and
retain data for re-mapping against updated
miRNA databases.
7. Summary
Colorectal cancer poses an increasingly important health burden globally, with apparent links to
diet that are unsurprising, given the liability of colorectum to be exposed to ingested compounds and
products of the gut microbiota. Cruciferous vegetables such as broccoli and cauliflower are inversely
correlated with colorectal cancer risk more strongly than other vegetables, and this is believed to be
at least partially attributable to the isothiocyanates obtained by consuming these vegetables, such as
SFN from broccoli. Isothiocyanates have been widely studied and shown to have anti-inflammatory,
antioxidant, and cytoprotective effects through well-studied mechanisms, such as the induction of
Nrf2. However, numerous anti-cancer effects have been demonstrated in vitro and in vivo that cannot
be solely attributed to Nrf2 induction, particularly those acting to suppress advanced cancer cell
proliferation. Since it is apparent that the effects of SFN are wide-ranging and complex—especially so
in cancer—it is clear that further knowledge regarding its bioactivities would aid in the development
of chemopreventive and/or chemotherapeutic strategies based upon it.
MiRNAs are known to translationally regulate the expression of least 30% of protein-coding genes
in humans and to play major roles in health and development, particularly in carcinogenesis. Their
biogenesis and activities are highly complex both in their nature and their potential for regulation.
There exists ample evidence in the published literature for the involvement of miRNAs in colorectal
carcinogenesis, and numerous reports exist of direct miRNA-mediated regulation of specific tumour
suppressor genes and/or oncogenes. Based upon existing knowledge regarding SFN’s activity, there
exist many plausible mechanisms by which SFN might modulate the expression of different miRNAs.
Therefore, the case for further investigation of the roles of miRNAs in the anti-cancer effects of SFN
is strong.
There are several types of approach to wide-scale miRNA expression profiling, including
array-based methods involving RT-qPCR or complementary probe hybridisation. These are relatively
fast and economical, but detectable miRNAs are limited to those known at a given point in time.
MiRNA cloning-deep sequencing is an alternative approach that can confer greater sensitivity
Nutrients 2017, 9, 902 14 of 19
that is not limited to the detection of miRNAs known at a given point in time. The challenge of
adapter-ligation bias toward certain miRNAs potentially encountered at the miRNA cloning stage
has been addressed by the development of Dalmay HD adapters—a library construction protocol
using these adapters has been published. The downsides of the library construction and sequencing
approach are its greater cost, time, and/or labour requirements. However, it is likely to be more
informative with regard to differential miRNA expression and thus worth considering where viable.
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